Introduction {#s1}
============

Immunotherapy has become a cornerstone in cancer treatment offering unexpected treatment opportunities for patients with metastatic, loco-regional, or even operable tumors in melanoma, lung, urothelial, and a number of other tumoral localizations.

Two main directions of intervention are now clinically available for manipulating immune checkpoints by either targeting CTLA-4 or PD-1/PD-L1. Our current understanding of the role of these two molecules is that anti CTLA-4 is involved in the lymphocyte proliferation process after antigen specific T-cell receptor activation while anti PD-1/PD-L1 act predominantly in peripheral tissues during the effector step. However, CTLA-4 is also expressed on regulatory T lymphocytes and is thus involved in peripheral inhibition of T cell proliferation.

Despite the effectiveness of these products, two main issues arise from theoretical and practical considerations.

First not all patients respond to therapy. To date prediction of response to immune checkpoint inhibitors is difficult and available predictive markers are not optimal. Secondly cancer may be associated with a number of autoimmune manifestations either as a paraneoplastic condition ([@B1]) or as comorbidities. In experimental models, knocking-out CTLA-4 results in a massive proliferation and lymphocytic infiltration of tissues ([@B2]) while PD-1 knock-down mice are prone to autoimmune disease \[reviewed in ([@B3])\]. These phenotypes can also be found in humans with CTLA-4 ([@B4], [@B5]) or PD-L1 ([@B6]) deficiency. Nevertheless, the mechanisms involved in antitumor immune response induced by checkpoint inhibitors may be different from those of autoimmune disease. However, it is clear that using checkpoint inhibitors to treat cancer poses the risk of a flare up of preexistent autoimmune disease and the development of new autoimmune manifestations in patients with preexisting autoimmunity even if present as a biological only manifestation (as for example positive auto antibodies).

Thus, these patients with preexisting autoimmune manifestations have been traditionally excluded from clinical trials as it was expected to have severe autoimmune manifestations which could exceed the potential benefit from tumor control. This subgroup of cancer patients harboring autoimmune manifestations is not trivial. Depending on the definition used, a large register-based analysis (SEER) including 2,10,509 patients with lung cancer identified between 13.5% (more restrictive definition) and 24.6% (more liberal definition) of cancer patients as having an autoimmune disease of any type ([@B7]). The most frequent manifestations found were rheumatoid arthritis (5.9%), psoriasis (2.8%), polymyalgia rheumatica (1.8%), Addison disease (1%), systemic lupus erythematosus (SLE-−0.9%), ulcerative colitis (0.8%), giant cell arteritis (0.8%), sicca syndrome (0.6%), regional enteritis (0.5%), and Meniere disease (0.5%). However, these autoimmune manifestations can be very broad as it has been recently reviewed for lung cancer in a series of articles curated by Jean Paul Scuiler ([@B1], [@B8]--[@B11]).

Thus, it is useful to perform, prior to any treatment, a careful evaluation of the possible autoimmune comorbidities in order to avoid possible harm, evaluate risk/benefit ratios, and anticipate possible complications.

Patients at Risk but Without Previous Clinical Evidence of Autoimmune Disease {#s2}
=============================================================================

In patient with lung cancer receiving checkpoint inhibitors, development of diverse IrAE is not completely random. Despite the fact that the incidence of IrAE increase with treatment duration, there is a pattern of developing specific organ manifestations in defined time frames. Thus, one can postulate that these IrAE develop in patients caring specific genotypes or having a previous immune priming predisposing for developing IrAE. Very little is known on this matter. Hasan Ali et al. ([@B12]) reported on a small series of 102 patients receiving anti PD-1/PD-L1 and anti CTLA-4 therapies, a very strong correlation between the presence of pruritus and the HLADRB1^\*^11:01 allele. Patient carrying these allele not only develop more pruritus than controls but also developed it earlier. Interesting, in previous investigations this specific allele has been associated with the development of atopic dermatitis in a small cohort of 185 children of Korean origin ([@B13]). The same allele has been associated with systemic sclerosis with anti-topoisomerase antibodies ([@B14]) or with the risk of developing systemic juvenile arthritis ([@B15]) or atopic dermatitis ([@B13]). The same Swiss group of Hasan Ali et al. also demonstrated an association trend between HLA DBQ1^\*^03:01 allele and the development of colitis. Again, this allele has been previously associated firmly with the development of inflammatory bowel disease ([@B16]). Similarly it is possible that some Single Nucleotide Polymorphism (SNP\'s), which are associated with a higher risk of autoimmune disease (colitis, diabetes, and allergy), positively impact the response rate to anti PD-1 therapy ([@B17]).

A systematic review of susceptible loci associated with development of IrAE\'s under checkpoint inhibitor therapy has been recently performed by Hoefsmit et al. ([@B18]) with a compartmentalized analysis based on affected organ and type of adverse effect. A huge number of susceptible loci, with a very variable physiologic/pathologic role, have been identified. However, these data can be hypothesis generating at most. At present time there is no sound information that can be applied to practice and there is no scientific basis to withhold checkpoint inhibitor treatment in people considered at risk based on these criteria.

Yoneshima et al. analyzed if pretreatment positive antinuclear antibodies (ANA) are associated either with IrAE or treatment response after administration of PD-1 inhibitors ([@B19]). They analyzed a group of 83 patients, of which 18 had preexisting positive serum ANA at a titer of 1:40 or higher. There was no statistical relationship between the presence of ANA and the risk of developing IrAE but there was an association trend between increasing ANA titers and the development of IrAE. Overall, response and disease control rates were similar in patients with or without ANA but there was also a higher PFS and OS in patients with negative ANA. A similar investigation was conducted by Sakakida et al. ([@B20]) which followed 191 patients treated with nivolumab, pembrolizumab, atezolizumab, or durvalumab and used a cutoff titer for positive ANA at 1:160. There was no significant difference in the development of IrAE between ANA positive and ANA negative patients with the exception of patients who developed colitis which had higher ANA titers than those who do not. Again, an elevated ANA titer was associated with a numerically lower disease control rate (37.5 and 67.5%) but this was not statistically significant (*p* = 0.08). Furthermore, for both series, the global numbers are rather small and the significance (both from statistical and clinical point of view) is debatable. Moreover, there are case reports of serious IrAE (i.e., fatal pneumonitis) that followed immune checkpoint administration in patients with pre-existing anti-synthetase syndrome ([@B21]).

To date, there is no sufficient data to warrant a systematic search for autoantibodies in cancer patients that are planned to receive checkpoint inhibitors. However, if knowledge of such positive finding is available, a clinical surveillance is warranted in order to identify, as early as possible, autoimmune manifestations associated with these autoantibodies.

People With Preexisting Clinically Diagnosed Autoimmune Disease {#s3}
===============================================================

Since these patients have been systematically excluded from clinical trials, subgroup analysis is scarcely available in the literature. Existing data originate from case reports, retrospective analyses of small series or registry data. Only one subgroup analysis of randomized trials is available but it does not cover the entire spectrum of autoimmune disease encountered in practice.

Case Reports
------------

A number of 37 publications reporting 41 cases have been found \[([@B22]--[@B59]); [Table 1](#T1){ref-type="table"}\]. Most cases were metastatic melanomas (*n* = 32), five non-small cell lung cancers, two Merkel cell carcinoma, one urothelial carcinoma, one colon cancer. These 41 cases received 44 immunotherapy treatments namely ipilimumab (*n* = 15), one reinduction ipilimumab, nivolumab (*n* = 9), or pembrolizumab (*n* = 18), one unclear, which globally reflect the successive market authorizations of these drugs. No reports combining immunotherapy with chemotherapy were found. Pre-existing autoimmune manifestations consisted of Crohn disease/ulcerative colitis (*n* = 8), rheumatoid arthritis (*n* = 7), psoriasis (*n* = 8), myasthenia gravis (*n* = −6), multiple sclerosis (*n* = 3), Hashimoto thyroiditis (*n* = 2), and one each of lupus, sarcoidosis, immune thrombocytopenia, melanoma associated retinopathy, Churg Strauss syndrome, granulomatosis with polyangiitis, hypothyroidy and type 1 diabetes, Bechet disease, and bullous pemphigoid. Globally a tumor effect of immunotherapy is reported for 40 out of the 44 treatments with six complete responses, 27 partial responses, three stable disease and four progressions. The response rate is 82.5% and the disease control rate is 90% which are very high figures but is it highly probable that this reflects a strong publication bias. In a majority of cases (*n* = 29, i.e., 65.6%) immunotherapy resulted in a flare up of the baseline disease which was managed with steroids or infliximab, adalimumab, or rituximab. In 10 cases (i.e., 22.7%) flare ups were considered severe/very severe with one death. In another case, a flare up of colitis was infliximab resistant and the patient subsequently developed a toxic epidermal necrosis and died. Only 16 cases had no flare up of the base line disease. Six of these patients developed other IrAE as pneumonitis, toxic epidermal necrosis, acute colitis, psoriasis, vasculitic neuropathy or acute interstitial nephritis. Overall, mortality due to disease flareup is about 4.5% and very severe (grade 4) toxicities unresponsive to steroids or even additional anti TNF alpha therapy was not uncommon. In only 12 cases no flare-up and no subsequent IrAE developed.

###### 

List of case report of Checkpoint inhibitors in patients with preexisting autoimmune diseases.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                         **Pre-existing autoimmune disease**          **Immunosuppressive treatment**                          **Cancer type**              **Drug received**     **Response**   **Disease flare Yes/No new autoimmune manifestation (treatment)**
  -------------------------------------- -------------------------------------------- -------------------------------------------------------- ---------------------------- --------------------- -------------- -----------------------------------------------------------------------------
  Gerdes et al. ([@B31])                 Multiple sclerosis                           No (minimal radiologic only disease)                     Melanoma                     Ipi                   Yes (PR)       Yes (massive flare)

  Gettings et al. ([@B32])               Multiple sclerosis                           --                                                       Melanoma                     Ipi                   Yes (PR)       Yes (Severe Flare)

  Kyi et al. ([@B38])\                   Multiple sclerosis                           IFN beta                                                 Melanoma                     Ipi                   No             No
  *N* =2                                                                                                                                                                                                         

                                         Rheumatoid arthritis                         MTX +PDN                                                 Melanoma                     Ipi                   Yes (PR)       No

  Benson et al. ([@B25])                 Rheumatoid arthritis                         Etanercept                                               Melanoma                     Ipi                   No             Yes\
                                                                                                                                                                                                                 Acute interstitialnephritis

                                                                                                                                                                            Pem                   Yes (PR)       Yes\
                                                                                                                                                                                                                 (hydroxychloroquine +prednisone)

  Puri and Homsi ([@B48])                Rheumatoid Arthritis                         PDN low dose                                             Melanoma                     Pem                   Yes (CR)       No

  Aya et al. ([@B23])                    Rheumatoid arthritis                         No                                                       Melanoma                     Ipi                   Yes (CR)       No Colitis(infliximab)

                                                                                                                                                                            Pem                   Yes (PR)       No Vasculiticneuropathy

  Hedge et al. ([@B34])                  Rheumatoid arthritis                         No                                                       Melanoma                     Pem                   Yes (PR)       --

  Kageyama et al. ([@B35])               Rheumatoid arthritis                         Salazopyrine                                             Melanoma                     Nivo                  Yes (CR)       No

  Zhu and Li ([@B57])                    Rheumatoid arthritis and Myasthenia gravis   No                                                       Melanoma                     Pem                   Yes (PR)       Yes (IvIg, plasmapheresis, PDN)

  Zaremba et al. ([@B56])                Myasthenia gravis                            AZT (followed by MMF and cyclosporine)                   Merkel cell carcinoma        Pem                   Yes (PR)       No

  Lau et al. ([@B39])                    Myasthenia gravis                            AZT                                                      Melanoma                     Pem                   --             Yes (steroids + IvIg)

  Maeda et al. ([@B40])                  Myasthenia gravis                            PDN                                                      Melanoma                     Nivo                  Yes (PR)       Yes (Self-limited)

  Cooper et al. ([@B28])                 Myasthenia gravis                            No (pyridostigmine)                                      NSCLC                        Nivo                  Yes (PR)       Yes (severe -- death)

  Phadke et al. ([@B46])\                Myasthenia gravis                            MMF                                                      Melanoma                     Pem                   Yes (PR)       Yes (Grade 4)
  *N* =2                                                                                                                                                                                                         

                                         Psoriasis/psoriatic arthritis                MTX                                                      Melanoma                     Pem                   Yes (CR)       Yes

  Roche et al. ([@B49])                  Psoriasis/psoriatic arthritis                --                                                       Merkel cell carcinoma        Pem                   Yes (PR)       No

  Sahuquillo-Torralba et al. ([@B50])    Psoriasis                                    Local treatment Psoriasis severity score 3 on 5% onBSA   NSCLC                        Pem                   Yes (PR)       Yes (severe -- Psoriasis score 22 on 81% of BSA;\
                                                                                                                                                                                                                 Pem continued and resolution with severity score 4 after acitretin 35 mg/d)

  De Bock et al. ([@B58])                Psoriasis                                    No                                                       Melanoma                     Nivo (previous Ipi)   Yes (SD)       Yes (local steroids and every 3 week Nivo)

  Chia and John ([@B27])                 Psoriasis                                    No                                                       NSCLC                        --                    --             Yes (severe flare)

  Kato et al. ([@B37])                   Psoriasis                                    No                                                       Melanoma                     Nivo                  --             Yes

  Matsumura et al. ([@B41])              Psoriasis                                    No                                                       Melanoma                     Nivo                  Yes (PR)       Yes\
                                                                                                                                                                                                                 Pneumonitis

  Esfahani and Miller ([@B29])           Psoriasis+ Crohn disease                     No                                                       Colon                        Pem                   Yes (PR)       Yes Psoriasis and gastrointestinal

  Frohne et al. ([@B30])                 Crohn disease                                Infliximab/AZT\                                          Melanoma                     Pem                   Yes (CR)       No
                                                                                      followed by Vedolizumab                                                                                                    

  Uemura et al. ([@B53])                 Crohn disease                                Tocilizumab                                              Melanoma                     Pem                   Yes (PR)       Yes (adalimumab)

  Gielisse and de Boer ([@B33])          Crohn disease                                No                                                       Melanoma                     Ipi                   Yes (PR)       Yes (manageable)

  Kamil et al. ([@B36])                  Crohn disease                                Mesalazine and PDN                                       NSCLC                        Ipi                   Yes (PR)       Yes (infliximab resistant)\
                                                                                                                                                                                                                 Toxic epidermal necrosis (death)

  Bostwick et al. ([@B26])               Ulcerative colitis                           No                                                       Melanoma                     Ipi                   Yes (PR)       Yes (infliximab)

                                                                                      AZT+ PDN                                                                              Reinduction Ipi       Yes (CR)       Yes\
                                                                                                                                                                                                                 Also new auto immunedisease

  Pedersen et al. ([@B45])\              Ulcerative colitis                           Infliximab                                               Melanoma                     Ipi                   Yes (PR)       No
  *N* =2                                                                                                                                                                                                         

                                         Bechet disease                               --                                                       Melanoma                     Ipi                   No             No

  Plachouri et al. ([@B47])\             Sarcoidosis                                  PDN low dose                                             Melanoma                     Ipi                   No             Yes (Flare with muscular involvement)
  Wieshaupt and Sunderkötter ([@B54])\                                                                                                                                                                           
  (duplicatepublication)                                                                                                                                                                                         

  Audemard et al. ([@B22])               Melanoma Associated Retinopathy              No                                                       Melanoma                     Ipi                   Yes (PR)       No (diminishing symptoms secondary to response)

  Beck et al. ([@B24])                   Bullous pemphigoid                           No                                                       Melanoma                     Ipi                   Yes (SD)       Yes -- steroids

                                                                                                                                                                            Pem                   Yes (SD)       Yes -- steroids

  Maul et al. ([@B42])                   Churg Strauss + Ipi induced colitis          --                                                       Melanoma                     Pem                   Yes (PR)       No

  Nabel et al. ([@B43])                  GPA (granulomatosis with polyangiitis)       Cyclophosphamide PTX, PDN                                MEN2+ Urothelial carcinoma   Pem                   Yes (PR)       Yes: PDN +rituximab

  Tagliamento et al. ([@B52])            SLE + HCV                                    PDN 5 mg\                                                Melanoma                     Nivo                  Yes (PR)       No
                                                                                      HCQ 200mg                                                                                                                  

  Stephen Bagley et al. ([@B51])         Immune thrombocytopenia                      No                                                       NSCLC                        Nivo                  Yes (PR)       Yes (mild)

  Akturk et al. ([@B59])                 Hypothyroidism\                              Immuno suppression (PDN, MMF, Tacro---graft)             Melanoma                     Pem + Nivo            --             Yes (graft rejection) Diabetic ketoacidosis and more severe hypothyroidia
                                         Type 1 diabetes\                                                                                                                                                        
                                         (+renal graft)                                                                                                                                                          

  Narita et al. ([@B44])\                Hashimoto thyroiditis                        No                                                       Melanoma                     Nivo                  Yes (PR)       Yes (serological)
  *N* = 2                                                                                                                                                                                                        

  Yonezaki et al. ([@B55])               Hashimoto thyroiditis                        --                                                       Melanoma                     Ipi (after Nivo)      Yes (PR)       Yes thyroid storm
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*HCQ, hidroxycloroquine; PDN, prednisone; AZT, azathioprine; MMF, mycophenolate mofetil; CycloA, ciclosporin A; Nivo, nivolumab; Pem, pembrolizumab; Ipi, ipilimumab; HCV, hepatitis virus C; SLE, systemic lupus erythematosus*.

Data From Clinical Trials
-------------------------

Even if patients with previous autoimmune disease have been excluded from clinical trials a number of patients have been nevertheless included. The FDA made a *post-hoc* analysis based on aggregate data from 22 trials with four Anti PD-1/PDL-1 agents that was published only in an abstract form ([@B60]). The series mainly include thyroid disease and cutaneous autoimmune manifestations (psoriasis and vitiligo)-−54.5% of cases. Worsening of the underlying disease occurred in 6--16 percent of the cases. Two grade 4 hyperglycemia were found in patients with preexisting diabetes, as well as three grade 3 hypothyroidy, psoriasis, and interstitial lung disease and one grade 3 ankylosing spondylitis. Only 8--9% of cases needed steroid prescription and duration of treatment varied between 145 and 196 days. Thus, in this population with probably a strong bias toward non-severe autoimmune manifestations, there are no consequent safety signals identified and administration of PD-1/PDL-1 inhibitors seems safe.

However, the report lacks data concerning the exact type of autoimmune condition for a large proportion of patients. Data on severity and treatment of baseline disease is also scarce and thus these results are to be interpreted with caution.

Case Series
-----------

We found five retrospective series in patients with melanoma ([@B61]--[@B65]) totalizing 150 cases with autoimmune disease previous to any treatment and 117 with autoimmune manifestations due to a previous therapy with ipilimumab which received another checkpoint inhibitor afterwards. In the series receiving only ipilimumab ([@B61], [@B63], [@B64]) the response rates varied between 12 and 50% (higher for smaller series) while in series with anti PD-1/PDL-1 ([@B62], [@B65]) the response rate was around 30% which is in line with what was described with these drugs in clinical trials. Between 27 and 50% of cases had a flare up of their baseline autoimmune condition while up to 30% of patients experienced the development of a new autoimmune toxicity. Grossly, the frequency of flare ups is similar to that of newly developed immune related manifestations. Severity of flare-ups was generally moderate, with 50% being more than grade one and no very severe cases (grade 4/5). Interestingly, in cases with an ipilimumab induced autoimmune disease, a flare up is rarely seen when subsequently treated with a PD-1/PDL-1 inhibitor. It seems that the presence of an autoimmune manifestation under CTLA-4 inhibition does not preclude anti PD-1/PDL-1 treatment but data in this area is still scare in order to make a firm clinical recommendation. Two case series of the same author ([@B66], [@B67]) reported 100 NSCLC cases and another one ([@B68]) 112 cases in multiple tumor types.

In these three series the tumor response rates varied between 45 and 51% while disease flare is seen in 17--47% of patients. Most of flare-ups are moderate (grade 3 or less). Between 25 and 42% of patients experienced a new IrAE, not related to the baseline autoimmune disease, during the course of treatment.

The reports do not always include detailed data concerning treatment received for the baseline autoimmune disease and thus it is difficult to derive clinical rules on which patients would eventually develop or not a flare-up of the baseline disease.

A number of 5 cases series with matched controls receiving the same immune checkpoint inhibitor but without autoimmune disease were published ([@B69]--[@B73]); these series included a total of 701 patients with a very large panel of autoimmune disorders ([Table 2](#T2){ref-type="table"}). Concerning antitumor efficacy, there was no difference between patients with or without previous autoimmune disease ([@B70], [@B73]). Up to 47% of patients experienced a flare up of their baseline disease and up to 42% developed a new IrAE. These figures, of newly generated IrAE, are comparable with those reported from randomized clinical trials ([@B74]). Severe and very severe cases (grade 3 and up) were not reported more frequently.

###### 

Case series with preexisting autoimmune disease (AD) treated with checkpoint inhibitors.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                                                   **Tumor**           ***N* =**                                                               **Baseline autoimmune dis**                                                                                                                                                       **Drug**                                     **Benefit**                                                                               **Toxicity**
  ---------------------------------------------------------------- ------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Post-hoc*** **analysis of clinical trial data**                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Weinstock et al. ([@B60])                                        All tumors          *N* = 552                                                               Thyroid *n* = 188--34%\                                                                                                                                                           Anti PD-1/PDL-1\                             No data (mean duration of treatment between 145 and 196 days)                             Worsening of baseline disease between 6 and 16%. Two grade 4 hyperglycemia and 7 grade 3. Steroids required in 8--9% of patients\
                                                                                                                                                               Psoriasis *n* = 70--12.5%\                                                                                                                                                        (no details)                                                                                                                           17% experienced anyIrAE
                                                                                                                                                               Vitiligo *n* = 44--8%\                                                                                                                                                                                                                                                                                                   
                                                                                                                                                               Other = 250                                                                                                                                                                                                                                                                                                              

  **Retrospective case series**                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Lee et al. ([@B61])                                              Melanoma            *N* = 8                                                                 RA (*n* = 8)\                                                                                                                                                                     Ipi                                          2 CR (25%)\                                                                               62.5% treat discontinuation\
                                                                                                                                                               50% MTX and/or AntiTNFa                                                                                                                                                                                                        2 PR\                                                                                     Median 2 cycles\
                                                                                                                                                                                                                                                                                                                                                                                              3 SD\                                                                                     Dis flare 50% grade 1 25%\
                                                                                                                                                                                                                                                                                                                                                                                              1 PD\                                                                                     50% more than grade 1\
                                                                                                                                                                                                                                                                                                                                                                                              4 responses at 11m                                                                        Grade 3 IrAE (All G3colitis)

  Johnson et al. ([@B63])                                          Melanoma            *N* = 30                                                                Rheumatoid arthritis *n* = 6\                                                                                                                                                     Ipi                                          PR + CR *n* = 6 (20%)\                                                                    27% had a flare -up\
                                                                                                                                                               Crohn/ulcerative colitis *n* = 6\                                                                                                                                                                                              Stable disease *n* = 3(10%)                                                               No severe cases\
                                                                                                                                                               Psoriasis *n* = 5\                                                                                                                                                                                                                                                                                                       33% had an IrAE (Colitis, Thyroiditis, Hypophysitis)
                                                                                                                                                               Multiple sclerosis *n* = 2\                                                                                                                                                                                                                                                                                              
                                                                                                                                                               Lupus *n* = 2\                                                                                                                                                                                                                                                                                                           
                                                                                                                                                               Sarcoidosis *n* = 2\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                               Thyroiditis *n* = 3\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                               Other *n* =7                                                                                                                                                                                                                                                                                                             

  Kahler et al. ([@B64])                                           Melanoma            *N* = 41 (with 44 AD conditions)                                        Thyroiditis *n* = 15, rheumatoid *n* = 11, dermatologic *n* = 10, Crohn\'s disease/ulcerative colitis *n* = 3, neurological *n* = 2, sarcoidosis *n* = 2, pancreatitis *n* = 1\   Ipi                                          1 CR, 4 PR ≥ 12% response rate                                                            *N* = 12 (29.2%) resulted in a flare up of preexisting disease\
                                                                                                                                                               *n* = 11 on immunosuppressors(25%)                                                                                                                                                                                                                                                                                       *N* = 12 (29.2%) had a new IrAE\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        *N* = 23 (56%) had no flare/no new IrAE

  Menzies et al. ([@B62])                                          Melanoma            *N* = 119\                                                              Not reported\                                                                                                                                                                     Pem 91.5%\                                   Response rate 33% in preexisting AD and 40% if IrAE on Ipi                                Flare up in 38%:\
                                                                                       95 with IrAE after Ipi\                                                 29% AD active symptoms                                                                                                                                                            Nivo 8.5%                                                                                                                              -RA 54%\
                                                                                       *N* = 52 preexisting AD                                                                                                                                                                                                                                                                                                                                                                          -Polymyalgia 100%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        -SJögren, thrombocytopenic purpura, 100%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        -No flare if Crohn or neurological disease\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        29% developed new adverse effects\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        No deaths

  Gutzmer et al. ([@B65])                                          Melanoma            *N* = 19                                                                Thyroiditis *n* = 6\                                                                                                                                                              Nivo 63%\                                    32% PR\                                                                                   42% had flare up in 3--20 weeks\
                                                                                                                                                               Psoriasis *n* = 3\                                                                                                                                                                Pem 37%                                      10% SD\                                                                                   -Rhumatological disease: 55%\
                                                                                                                                                               Spondylarthritis/ankylosing spondylitis/\                                                                                                                                                                                      58% PD                                                                                    -Colitis 100%\
                                                                                                                                                               Myositis/polymyalgia/rheumatoid arthritis *n* = 6\                                                                                                                                                                                                                                                                       -Psoriasis 50%\
                                                                                                                                                               Sarcoidosis *n* = 2\                                                                                                                                                                                                                                                                                                     -Thyroiditis20%\
                                                                                                                                                               Multiple sclerosis/Guillain Barré/Ulcerative colitis/Churg Strauss *n* = 1each                                                                                                                                                                                                                                           16% had a new IrAE

                                                                                       *N* = 22                                                                IrAE induced by Ipi\                                                                                                                                                              Nivo 41%\                                                                                                                              Only 1/22 Flare-up (5%)\
                                                                                                                                                               Colitis *n* = 11 (Gr 3 = 7 GR4 = 1)\                                                                                                                                              Pem 59%                                                                                                                                23% developed another IrAE
                                                                                                                                                               Hypophysitis *n* = 10 (Gr3 = 4)\                                                                                                                                                                                                                                                                                         
                                                                                                                                                               Thyroiditis *n* = 3\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                               Hepatitis *n* =1                                                                                                                                                                                                                                                                                                         

  Leonardi et al. ([@B66])                                         NSCLC               *N* = 46                                                                Not reported\                                                                                                                                                                     Anti PD-1 (no details)                       No data                                                                                   17% flare of baseline disease\
                                                                                                                                                               13% active disease\                                                                                                                                                                                                                                                                                                      26% developed other IrAE\
                                                                                                                                                               19% receive immune treat                                                                                                                                                                                                                                                                                                 No grade 4--5

  Leonardi et al. ([@B67])                                         NSCLC               *N* = 56                                                                Rheumatologic *n* = 25(45%)\                                                                                                                                                      Nivo 80%\                                    PR 22%\                                                                                   23% flare of baseline disease\
                                                                                                                                                               Dermatologic *n* = 16 (29%)\                                                                                                                                                      Pem 18%\                                     SD 31%\                                                                                   -13% grade 3, 0% Grade 4 and 5\
                                                                                                                                                               Endocrine *n* = 9 (16%)\                                                                                                                                                          Atezo 2%                                     PD 47%\                                                                                   -50% of symptomatic had a flare vs. 18% of asymptomatic patients\
                                                                                                                                                               Crohn/ulcerative colitis *n* = 6 (11%)\                                                                                                                                                                                        No relation of flare or steroids at beginning of treatment with response                  -Rheumatologic patients 40% flare vs. 10% other\
                                                                                                                                                               Myastenia/Multiple sclerosis *n* = 3(5%)                                                                                                                                                                                                                                                                                 38% developed another IrAE\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        5% developed both

  Tison et al. ([@B68])                                            Melanoma59%\        *N* = 112                                                               Psoriasis *n* = 31 (28%)\                                                                                                                                                         Ipi *n* = 13%\                               30% PR\                                                                                   47% flare of baseline disease\
                                                                   NSCLC 35%\                                                                                  Rheumatoid arthritis *n* = 20 (18%)\                                                                                                                                              Nivo 56%\                                    15%CR                                                                                     -70% mild, 30% severe\
                                                                   Urothelial 3%\                                                                              Inflammatory bowel dis *n* = 14 (13%)\                                                                                                                                            Pem 24%\                                                                                                                               -45% required steroid\
                                                                   MCC 1.5%                                                                                    Spondilartritis *n* = 5 (4,5%)\                                                                                                                                                   Ipi + Nivo 3%\                                                                                                                         -9%other immunosuppression\
                                                                                                                                                               Lupus *n* = 7 (6,3%)\                                                                                                                                                             Atezo 2%\                                                                                                                              42% another IrAE\
                                                                                                                                                               Polymyalgia/Gian cell arteritis *n* = 7\                                                                                                                                          Ave 2%                                                                                                                                 -60% mild 40% severe\
                                                                                                                                                               Other *n* = 28(25%)                                                                                                                                                                                                                                                                                                      18% had both flare + new IrAE\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        1 death

  **Series including a control group with ICI treated patients**                                                                                                                                                                                                                                                                                                                                                                                                                        

  Danlos et al. ([@B69])                                           Melanoma 80%\       *N* = 45 vs. 352 controls                                               Rheumatic disease, *n* = 7 (13%)\                                                                                                                                                 Pem 75.6%\                                   Not reported                                                                              20 (44.4%) experienced and IrAE\
                                                                   NSCLC 13.3%\                                                                                Dermatologic disease, *n* = 33 (62%)\                                                                                                                                             Nivo 22.2%\                                                                                                                            Of which 11 (55%)\
                                                                   Other 6.7%                                                                                  Endocrine disease, *n* = 9 (17%)\                                                                                                                                                 Ave 2.2%\                                                                                                                              where flare UP (i.e., *n* = 11/45--24.5%) 10 patients developed a new IrAE\
                                                                                                                                                               Neurologic disease, *n* = 3 (5.7%)\                                                                                                                                               9 patients pretreated with AntiCTLA-4/PD-1                                                                                             Only in 5 of the 20 patients ICI treatment was stopped\
                                                                                                                                                               Hematologic disease, *n* = 1 (1.9%)\                                                                                                                                                                                                                                                                                     After excluding vitiligo 51,6 patients did not develop an IrAE under ICItreatment
                                                                                                                                                               Symptomatic stable disease 50.9%\                                                                                                                                                                                                                                                                                        
                                                                                                                                                               Flare (at ICI initiation) = 5.7%\                                                                                                                                                                                                                                                                                        
                                                                                                                                                               6 ICI pretreated experienced colitis (*n* = 3), thyroiditis, hypophisitis, and nephritis                                                                                                                                                                                                                                 

  Cortellini et al. ([@B70])                                       NSCLC 65.5%\        *N* = 85 vs. 666 controls                                               Thyroid disorder *n* = 51\                                                                                                                                                        No data                                      Response rate 35,3%\                                                                      With preexisting AD:\
                                                                   Melanoma 21%\                                                                               (60%) Dermatologic *n* = 14 (16.4%)\                                                                                                                                                                                           No difference with or without AD                                                          -All grade 65.9% (95%CI 49.7--85.5)\
                                                                   RCC 12.5%\                                                                                  Rheumatologic *n* = 10 (11.8%)\                                                                                                                                                                                                                                                                                          -G3/G4 9.4% (95%CI 4.1--18.5%)\
                                                                   Other1%                                                                                     Gastrointestinal/hepatic *n* = 4 (4.7%)\                                                                                                                                                                                                                                                                                 -Flare of baseline Disease 47.1%\
                                                                                                                                                               Neuro-/Nephro- *n* = 1 (1.2%) each\                                                                                                                                                                                                                                                                                      -No Diff between active and inactive disease at baseline\
                                                                                                                                                               Multiple *n* = 4(4.7%)                                                                                                                                                                                                                                                                                                   Without preexisting AD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        -All grades 39,9% (95%CI 35.2--45)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        -G3/G4 8.8% (95%CI6.7--11.4)

  Ricther et al. ([@B71])                                          Melanoma 63%\       *N* = 16 (out of 33 with preexisting AD and 700 ICI treated patients)   Polymyalgia rheumatica *n* = 5 (31%)\                                                                                                                                             Ipi 31%\                                                                                                                               IrAE developed in *n* = 6 (38%)\
                                                                   NSCLC 25%\                                                                                  Rheumatoid arthritis *n* = 5 (31%)\                                                                                                                                               Nivo 44%\                                                                                                                              Colitis *n* = 3 Only 1 case had a flare of baseline Rheumatic Disease\
                                                                   Hematologic13%                                                                              Giant Cell arteritis *n* = 2 (13%)\                                                                                                                                               Pem 31%                                                                                                                                5 of 6 occurred during first 4 cycles\
                                                                                                                                                               Sjogren syndrome *n* = 2 (13%)\                                                                                                                                                                                                                                                                                          4 of 6 were grade 3 or 4\
                                                                                                                                                               Lupus *n* = 2 (13%)\                                                                                                                                                                                                                                                                                                     All managed with steroids. One treated with another IC with no relapse
                                                                                                                                                               Ankylosing spondylitis *n* = 1\                                                                                                                                                                                                                                                                                          
                                                                                                                                                               Idiopathic aortitis *n* = 1\                                                                                                                                                                                                                                                                                             
                                                                                                                                                               Sarcoidosis *n* = 1\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                               Urticarial vasculitis *n* =1                                                                                                                                                                                                                                                                                             

  Khozin et al. ([@B73])                                           NSCLC               538 with AD out of 2,425 patients                                       Not reported                                                                                                                                                                      Not reported                                 No difference for PFS, OS, Time to treatment discontinuation and time to next treatment   No increasing IrAE in patients with preexisting autoimmune disease

  Shah et al. ([@B72])                                             Melanoma 45%\       *n* = 22 with AD out of 638                                             Hypothyroidism (36.4%)\                                                                                                                                                           Ipi 45%\                                     No data                                                                                   Only *n* = 4 (18%) had an exacerbation of previous Autoimmune disease\
                                                                   Lung Cancer 18%\                                                                            Graves disease (9%)\                                                                                                                                                              Pem 41%\                                                                                                                               19 out of 22 had a new IrAE\
                                                                   Other 37%                                                                                   Psoriasis, vitiligo (*n* = 2--9%)\                                                                                                                                                Nivo 27%                                                                                                                               Pulmonary *n* = 10\
                                                                                                                                                               each Ulcerative colitis (*n* = 2--9%)\                                                                                                                                                                                                                                                                                   Gastrointestinal *n* = 6\
                                                                                                                                                               Type 1 diabetes, ankylosing spondylitis, lupus, nephropathy (*n* = 1--4.5%each)                                                                                                                                                                                                                                          Heptic *n* = 5\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Renal *n* = 3\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Hypothyroidism *n* = 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Dermatological *n* = 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Musculoskeletal *n* = 2\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Hypophisitis *n* =1

  Kehl et al. ([@B75])                                             Lung cancer 42%\    179 (strict criteria)\                                                  Not reported                                                                                                                                                                      Nivo 52%\                                    Mean treatment duration 13.7 weeks                                                        Pre-existing autoimmune disease not related with all cause hospitalization but related with hospitalization for an IrAE (HR 1.81 95%CI 1.21--2.71) and prescription of steroids (HR 1.93 95%CI 1.35--2.76)
                                                                   Melanoma 34%\       Out of 4,438 treated patients                                                                                                                                                                                                                             Pem 20%\                                                                                                                               
                                                                   Renal 9%\                                                                                                                                                                                                                                                                     Ipi 21%\                                                                                                                               
                                                                   Urothelial 3.5%\                                                                                                                                                                                                                                                              Ipi + Nivo 5%\                                                                                                                         
                                                                   Head and neck 5%\                                                                                                                                                                                                                                                             Atezo 3%                                                                                                                               
                                                                   Other6.5%                                                                                                                                                                                                                                                                                                                                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Finally, an analysis of the SEER registry data ([@B75]) showed that a preexisting autoimmune disorder is not related to all cause hospitalization but is associated with hospitalization related to the development of IrAE and with steroid prescription.

Conclusions {#s4}
===========

While it is difficult to aggregate such very disparate data some conclusion may still be extracted. First, patients with autoimmune disorders seems to derive the same benefit in term of tumor response compared with people without autoimmune disorders. Conflicting data exist concerning the association between autoimmunity or IrAE and tumor response, with both positive and negative investigations ([@B76]--[@B79]). Much more research is needed in this area. Thus, there is no an "a priori" reason to deny a potential effective treatment to these patients. Weather this group of patients experience more long-term benefit is still a matter of investigation.

Concerning safety, these patients seem to generate the same spectrum, number, and severity of IrAE (other than the flare up of their baseline autoimmune condition) as patients without preexisting autoimmune disease and thus need to be followed-up similarly. The question arises for the flare-up of their autoimmune condition. At least 30% to a maximum of 80% of patients, depending on series and type of baseline autoimmune disease, do not experience a flare up. In general, people with skin autoimmune disorders can be managed safely even in case of very severe flares ([@B50]). The same apply for those with thyroid dysfunction but severe hyperthyroidism can be encountered even in previously chronic hypothyroid patients ([@B55]).

Some data exist for patients with rheumatic disease, and it seems that at least 50% of them experience a disease flare. Grade 4 and 5 flare-ups seems infrequent and generally are manageable with steroids and anti-TNF medications. These patients can receive checkpoint inhibitors provided that no best option is available, they are informed on the potential disease flare and a careful follow-up is instituted.

Insufficient data exist for patients with inflammatory bowel disease. When these manifestations develop during a previous anti CTLA-4 treatment, the relapse rate under anti PD-1/PDL-1 therapy seems low and it is probable that these patients can be safely treated.

There is a need for more research in groups of patients with inflammatory bowel disease which receive checkpoint inhibitors for the first time. Their administration clearly poses some risks, but it needs to be evaluated taking into account the effectiveness of available alternatives and the patient should understand the potential benefits and harms as well as the risk -benefit ratio.

Based in SEER data, administration of immune checkpoint inhibitors do not result in excess hospitalizations compared to similar patients without autoimmune disease but the hospitalizations are strongly related to the development or flare up of autoimmune conditions. An observational trial concerning ipilimumab in patients with melanoma and underlying autoimmune diseases ([@B80]) has been performed but, to our best knowledge, results have not yet been reported.
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